Active specific immunotherapy with therapeutic melanoma vaccines
HAYES, Inc.
Record ID 32006001076
English
Authors' objectives:
Active specific immunotherapy with therapeutic melanoma vaccines is proposed for selected categories of patients with malignant melanoma. The goals of treatment with melanoma vaccines include tumor regression, prolongation of disease-free and overall survival, and improved quality of life. Active specific immunotherapy is designed to elicit an immune response by recruiting specific effector cells to produce antibodies or a T-cell response directed against one or more specific tumor antigens. This is in contrast to active immunotherapy using nonspecific agents that stimulate the immune system globally, such as cytokines, and passive immunotherapy using agents that directly or indirectly mediate tumor killing, such as monoclonal antibodies.
Authors' methods:
Review
Details
Project Status:
Completed
Year Published:
2006
URL for published report:
This report has been updated. The current report can be pruchased from: http://www.hayesinc.com/hayes/crd/?crd=1811
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Cancer Vaccines
- Immunotherapy, Active
- Melanoma
- Skin Neoplasms
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2006 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.